Neuropilin 1

NRP1
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
Aliases NRP1, BDCA4, CD304, NP1, NRP, VEGF165R, Neuropilin 1
External IDs MGI: 106206 HomoloGene: 2876 GeneCards: NRP1
Genetically Related Diseases
tetralogy of Fallot[1]
RNA expression pattern




More reference expression data
Orthologs
Species Human Mouse
Entrez

8829

18186

Ensembl

ENSG00000099250

ENSMUSG00000025810

UniProt

O14786

P97333

RefSeq (mRNA)

NM_001024628
NM_001024629
NM_001244972
NM_001244973
NM_003873

NM_008737

RefSeq (protein)

NP_001019799.1
NP_001019800.1
NP_003864.4

NP_032763.2

Location (UCSC) Chr 10: 33.18 – 33.34 Mb Chr 8: 128.36 – 128.51 Mb
PubMed search [2] [3]
Wikidata
View/Edit HumanView/Edit Mouse

Neuropilin-1 is a protein that in humans is encoded by the NRP1 gene.[4][5][6] In humans, the neuropilin 11 gene is located at 10p11.22. This is one of two human neuropilins.

Function

NRP1 is a membrane-bound coreceptor to a tyrosine kinase receptor for both vascular endothelial growth factor (VEGF; MIM 192240) and semaphorin (see SEMA3A; MIM 603961) family members. NRP1 plays versatile roles in angiogenesis, axon guidance, cell survival, migration, and invasion.[supplied by OMIM][6]

Interactions

Neuropilin 1 has been shown to interact with Vascular endothelial growth factor A.[4][7]

Implication in cancer

Neuropilin 1 has been implicated in the vascularization and progression of cancers. In vitro and in vivo mouse studies have shown membrane bound NRP1 to be proangiogenic and promotes the vascularization of prostate tumors.[8] NRP1 expression levels have been shown to be elevated in a number of human patient tumor samples, including brain, prostate, breast, colon, and lung cancers and is associated with metastasis.[9][10][11][12][13] Elevated NRP1 expression is also correlated with the invasiveness of non-small cell lung cancer both in vitro and in vivo.[13]

Target for cancer therapies

As a co-receptor for VEGF, NRP1 is a potential target for cancer therapies. A synthetic peptide, EG3287, was generated in 2005 and has been shown to block NRP1 activity.[14] EG3287 has been shown to induce apoptosis in tumor cells with elevated NRP1 expression.[14] A patent for EG3287 was filed in 2002 and approved in 2003.[15] As of 2015 there were no clinical trials ongoing or completed for EG3287 as a human cancer therapy.

Interestingly, soluble NRP1 has the opposite effect of membrane bound NRP1 and has anti-VEGF activity. In vivo mouse studies have shown that injections of sNRP-1 inhibits progression of acute myeloid leukemia in mice.[16]

References

  1. "Diseases that are genetically associated with NRP1 view/edit references on wikidata".
  2. "Human PubMed Reference:".
  3. "Mouse PubMed Reference:".
  4. 1 2 Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M (Mar 1998). "Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor". Cell. 92 (6): 735–45. doi:10.1016/S0092-8674(00)81402-6. PMID 9529250.
  5. Chen H, Chédotal A, He Z, Goodman CS, Tessier-Lavigne M (Sep 1997). "Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III". Neuron. 19 (3): 547–59. doi:10.1016/S0896-6273(00)80371-2. PMID 9331348.
  6. 1 2 "Entrez Gene: NRP1 neuropilin 1".
  7. Mamluk R, Gechtman Z, Kutcher ME, Gasiunas N, Gallagher J, Klagsbrun M (Jul 2002). "Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain". The Journal of Biological Chemistry. 277 (27): 24818–25. doi:10.1074/jbc.M200730200. PMID 11986311.
  8. Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M (Dec 2000). "Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression". FASEB Journal. 14 (15): 2532–9. doi:10.1096/fj.00-0250com. PMID 11099472.
  9. Fakhari M, Pullirsch D, Abraham D, Paya K, Hofbauer R, Holzfeind P, Hofmann M, Aharinejad S (Jan 2002). "Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and -2 in human neuroblastoma". Cancer. 94 (1): 258–63. doi:10.1002/cncr.10177. PMID 11815985.
  10. Latil A, Bièche I, Pesche S, Valéri A, Fournier G, Cussenot O, Lidereau R (Mar 2000). "VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms". International Journal of Cancer. Journal International Du Cancer. 89 (2): 167–71. doi:10.1002/(SICI)1097-0215(20000320)89:2<167::AID-IJC11>3.0.CO;2-9. PMID 10754495.
  11. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, Mercurio AM (Aug 2001). "Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells". Cancer Research. 61 (15): 5736–40. doi:10.3892/ijo.32.1.41. PMID 11479209.
  12. Parikh AA, Fan F, Liu WB, Ahmad SA, Stoeltzing O, Reinmuth N, Bielenberg D, Bucana CD, Klagsbrun M, Ellis LM (Jun 2004). "Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis". The American Journal of Pathology. 164 (6): 2139–51. doi:10.1016/s0002-9440(10)63772-8. PMID 15161648.
  13. 1 2 Hong TM, Chen YL, Wu YY, Yuan A, Chao YC, Chung YC, Wu MH, Yang SC, Pan SH, Shih JY, Chan WK, Yang PC (Aug 2007). "Targeting neuropilin 1 as an antitumor strategy in lung cancer". Clinical Cancer Research. 13 (16): 4759–68. doi:10.1158/1078-0432.CCR-07-0001.
  14. 1 2 Barr MP, Byrne AM, Duffy AM, Condron CM, Devocelle M, Harriott P, Bouchier-Hayes DJ, Harmey JH (Jan 2005). "A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells". British Journal of Cancer. 92 (2): 328–33. doi:10.1038/sj.bjc.6602308.
  15. "Vegf peptides and their use (WO 2003082918 A1)" (patent). Oct 9, 2003.
  16. Gagnon ML, Bielenberg DR, Gechtman Z, Miao HQ, Takashima S, Soker S, Klagsbrun M (Mar 2000). "Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity". Proceedings of the National Academy of Sciences of the United States of America. 97 (6): 2573–8. doi:10.1073/pnas.040337597. PMC 15970Freely accessible. PMID 10688880.

Further reading

  • Zachary I, Gliki G (Feb 2001). "Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family". Cardiovascular Research. 49 (3): 568–81. doi:10.1016/S0008-6363(00)00268-6. PMID 11166270. 
  • He Z, Tessier-Lavigne M (Aug 1997). "Neuropilin is a receptor for the axonal chemorepellent Semaphorin III". Cell. 90 (4): 739–51. doi:10.1016/S0092-8674(00)80534-6. PMID 9288753. 
  • Giger RJ, Urquhart ER, Gillespie SK, Levengood DV, Ginty DD, Kolodkin AL (Nov 1998). "Neuropilin-2 is a receptor for semaphorin IV: insight into the structural basis of receptor function and specificity". Neuron. 21 (5): 1079–92. doi:10.1016/S0896-6273(00)80625-X. PMID 9856463. 
  • Chen H, He Z, Bagri A, Tessier-Lavigne M (Dec 1998). "Semaphorin-neuropilin interactions underlying sympathetic axon responses to class III semaphorins". Neuron. 21 (6): 1283–90. doi:10.1016/S0896-6273(00)80648-0. PMID 9883722. 
  • Takahashi T, Nakamura F, Jin Z, Kalb RG, Strittmatter SM (Oct 1998). "Semaphorins A and E act as antagonists of neuropilin-1 and agonists of neuropilin-2 receptors". Nature Neuroscience. 1 (6): 487–93. doi:10.1038/2203. PMID 10196546. 
  • Rossignol M, Beggs AH, Pierce EA, Klagsbrun M (May 1999). "Human neuropilin-1 and neuropilin-2 map to 10p12 and 2q34, respectively". Genomics. 57 (3): 459–60. doi:10.1006/geno.1999.5790. PMID 10329017. 
  • Makinen T, Olofsson B, Karpanen T, Hellman U, Soker S, Klagsbrun M, Eriksson U, Alitalo K (Jul 1999). "Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1". The Journal of Biological Chemistry. 274 (30): 21217–22. doi:10.1074/jbc.274.30.21217. PMID 10409677. 
  • Cai H, Reed RR (Aug 1999). "Cloning and characterization of neuropilin-1-interacting protein: a PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1". The Journal of Neuroscience. 19 (15): 6519–27. PMID 10414980. 
  • Takahashi T, Fournier A, Nakamura F, Wang LH, Murakami Y, Kalb RG, Fujisawa H, Strittmatter SM (Oct 1999). "Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors". Cell. 99 (1): 59–69. doi:10.1016/S0092-8674(00)80062-8. PMID 10520994. 
  • Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, Chedotal A, Winberg ML, Goodman CS, Poo M, Tessier-Lavigne M, Comoglio PM (Oct 1999). "Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates". Cell. 99 (1): 71–80. doi:10.1016/S0092-8674(00)80063-X. PMID 10520995. 
  • Gagnon ML, Bielenberg DR, Gechtman Z, Miao HQ, Takashima S, Soker S, Klagsbrun M (Mar 2000). "Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity". Proceedings of the National Academy of Sciences of the United States of America. 97 (6): 2573–8. doi:10.1073/pnas.040337597. PMC 15970Freely accessible. PMID 10688880. 
  • Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G (Jun 2000). "Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]". The Journal of Biological Chemistry. 275 (24): 18040–5. doi:10.1074/jbc.M909259199. PMID 10748121. 
  • Fuh G, Garcia KC, de Vos AM (Sep 2000). "The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1". The Journal of Biological Chemistry. 275 (35): 26690–5. doi:10.1074/jbc.M003955200. PMID 10842181. 
  • Rossignol M, Gagnon ML, Klagsbrun M (Dec 2000). "Genomic organization of human neuropilin-1 and neuropilin-2 genes: identification and distribution of splice variants and soluble isoforms". Genomics. 70 (2): 211–22. doi:10.1006/geno.2000.6381. PMID 11112349. 
  • Simpson JC, Wellenreuther R, Poustka A, Pepperkok R, Wiemann S (Sep 2000). "Systematic subcellular localization of novel proteins identified by large-scale cDNA sequencing". EMBO Reports. 1 (3): 287–92. doi:10.1093/embo-reports/kvd058. PMC 1083732Freely accessible. PMID 11256614. 
  • Whitaker GB, Limberg BJ, Rosenbaum JS (Jul 2001). "Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121)". The Journal of Biological Chemistry. 276 (27): 25520–31. doi:10.1074/jbc.M102315200. PMID 11333271. 
  • Walter JW, North PE, Waner M, Mizeracki A, Blei F, Walker JW, Reinisch JF, Marchuk DA (Mar 2002). "Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma". Genes, Chromosomes & Cancer. 33 (3): 295–303. doi:10.1002/gcc.10028. PMID 11807987. 
This article is issued from Wikipedia - version of the 5/21/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.